Claims
- 1. A hetero-linked phenylglycinolamide of the formula (I): in whichA represents pyridyl or quinolyl, each of which is optionally substituted, optionally also via a nitrogen atom thereof, by 1 to 3 substituents independently selected from the group consisting of: a) halogen, b) trifluoromethyl, c) carboxyl, d) hydroxyl, e) nitro, f) cycloalkyl having 3 to 7 carbon atoms, g) benzyl, h) phenyl, i) benzyloxy, j) straight-chain or branched alkyl having up to 6 carbon atoms, k) straight-chained or branched alkoxy having up to 6 carbon atoms; or l) straight-chain or branched alkoxycarbonyl having up to 6 carbon atoms, D represents an oxygen atom or a radical of the formula —CO—, —(CO)a—NR7, —(CH2)bS—, —(CH2)c—NR8 or —CH═CH—, in which a, b and c are identical or different and denote a number 0 or 1, R7 and R8 are identical or different and denote hydrogen, straight-chain or branched alkyl or acyl each having up to 6 carbon atoms, phenyl or benzyl, the phenyl or benzyl optionally being substituted up to 2 times identically or differently by nitro, halogen, trifluoromethyl or by straight-chain or branched alkyl or alkoxy each having up to 3 carbon atoms, E and L are identical or different and represents hydrogen, cycloalkyl having 3 to 8 carbon atoms, azido, hydroxyl, halogen, straight-chain or branched alkyl, alkoxy or alkenyl each having up to 6 carbon atoms, R1 represents cycloalkyl having 3 to 8 carbon atoms, or represents straight-chain or branched alkyl having up to 10 carbon atoms, R2 represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, R3 represents a radical of the formula in which R9 denotes hydrogen or a radical of the formula CH2—OH, R10 denotes phenyl which is optionally substituted up to 3 times identically or differently by hydroxyl, halogen or straight-chain or branched alkyl having up to 5 carbon atoms, or a salt thereof.
- 2. A hetero-linked phenylglycinolamide of the formula (I) according to claim 1, in whichA represents pyridyl or quinolyl, each of which is optionally substituted, optionally also via a nitrogen atom thereof, by 1 to 3 substituents independently selected from the group consisting of: a) fluorine, b) chlorine, c) bromine, d) trifluoromethyl, e) carboxyl, f) hydroxyl, g) nitro, h) cyclopropyl, i) cyclopentyl, j) cyclohexyl, k) benzyl, l) phenyl, m) benzyloxy, n) straight-chain or branched alkyl having up to 4 carbon atoms, o) straight-chain or branched alkoxy having up to 4 carbon atoms; or p) straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms, D represents an oxygen atom or a radical of the formula —CO—, —(CO)a—NR7, —(CH2)bS—, —(CH2)c—NR8 or —CH═CH—, in which a, b and c are identical or different and denote a number 0 or 1, R7 and R8 are identical or different and denotes hydrogen, straight-chain or branched alkyl or acyl each having up to 5 carbon atoms, phenyl or benzyl, the phenyl or benzyl optionally being substituted up to 2 times identically or differently by nitro, fluorine, chlorine, bromine, trifluoromethyl or by straight-chain or branched alkyl or alkoxy each having up to 3 carbon atoms, E and L are identical or different and represent hydrogen, cyclopropyl, cyclopentyl, cyclohexyl, azido, hydroxyl, fluorine, chlorine, bromine, straight-chain or branched alkyl, alkoxy or alkenyl each having up to 3 carbon atoms, R1 represents cyclopropyl, cyclobutyl, cyclopentyl cyclohexyl or cycloheptyl, or straight-chain or branched alkyl having up to 8 carbon atoms, R2 represents hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms, R3 represents a radical of the formula, in which R9 denotes hydrogen or a radical of the formula CH2—OH, R10 denotes phenyl, which is optionally substituted up to 2 times identically or differently by hydroxyl, fluorine, chlorine, bromine or straight-chain or branched alkyl having up to 3 carbon atoms, or a salt thereof.
- 3. A hetero-linked phenylglycinolamide of the formula (I) according to claim 1, in whichA represents pyridyl or quinolyl, each of which is optionally substituted, optionally also via a nitrogen atom thereof, by 1 to 2 substituents independently selected from the group consisting of: a) fluorine, b) chlorine, c) trifluoromethyl, d) carboxyl, e) hydroxyl, f) nitro, g) cyclohexyl, h) benzyl, i) phenyl, j) benzyloxy, k) straight-chain or branched alkyl having up to 3 carbon atoms, l) straight-chain or branched alkoxy having up to 3 carbon atoms; or m) straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms, D represents an oxygen or a radical of the formula —CO—, —(CO)a—NR7, —(CH2)bS—, —(CH2)c—NR8 or —CH═CH—, in which a, b and c are identical or different and denote a number 0 or 1, R7 and R8 are identical or different and denote hydrogen, methyl, ethyl, acetyl, phenyl or benzyl, the phenyl or benzyl optionally being substituted up to 2 times identically or differently by nitro, fluorine, chlorine, bromine, trifluoromethyl or by straight-chain or branched alkyl or alkoxy each having up to 3 carbon atoms, E and L are identical or different and represents hydrogen, fluorine, chlorine or bromine, R1 represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl or straight-chain or branched alkyl having up to 8 carbon atoms, R2 represents hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms, R3 represents a radical of the formula in which R9 denotes hydrogen or a radical of the formula CH2—OH, R10 denotes phenyl which is optionally substituted up to 2 times identically or differently by hydroxyl, fluorine, chlorine, methyl or ethyl, or a salt thereof.
- 4. A composition for the treatment of atherosclerosis comprising an amount effective therefor of a compound or salt thereof according to claim 1 and a pharmacologically acceptable diluent.
- 5. A method of treating atherosclerosis in a patient in need thereof which comprises administering to such patient an amount effective therefor of a compound or salt thereof according to claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
196 15 262 |
Apr 1996 |
DE |
|
Parent Case Info
This application is a division of U.S. Ser. No. 09/205,772, (U.S. Pat. No. 6,191,157) filed Dec. 4, 1998, now allowed; which is, in turn, a division of U.S. Ser. No. 08/833,826, filed Apr. 10, 1997, now U.S. Pat. No. 5,892,114, issued Apr. 6, 1999.
Non-Patent Literature Citations (1)
Entry |
Huang et al. (DN 111:57510 abstract of J. Med. Chem. 32(8), 1836-42). |